Accustem Sciences Inc. – OTC:ACUT

Accustem Sciences stock price today

$1.78
+1.43
+411.64%
Financial Health
0
1
2
3
4
5
6
7
8
9

Accustem Sciences stock price monthly change

+2.05%
month

Accustem Sciences stock price quarterly change

+2.05%
quarter

Accustem Sciences stock price yearly change

-51.65%
year

Accustem Sciences key metrics

Market Cap
N/A
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-61.84
Revenue
N/A
EBITDA
-1.11M
Income
-681.44M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Accustem Sciences stock price history

Accustem Sciences stock forecast

Accustem Sciences financial statements

Accustem Sciences Inc. (OTC:ACUT): Profit margin
Dec 2022 0 -677.97M
Mar 2023 0 -2.50M
Jun 2023 0 -372.75K
Sep 2023 0 -598.52K
Accustem Sciences Inc. (OTC:ACUT): Debt to assets
Dec 2022 939689 1.07M 114.85%
Mar 2023 247559 1.19M 482.41%
Jun 2023 458530 1.76M 385%
Sep 2023 257575 2.14M 832%
Accustem Sciences Inc. (OTC:ACUT): Cash Flow
Dec 2022 -490.72K 0 -107.25K
Mar 2023 -446.09K -8.20K -107.25K
Jun 2023 0 0 350K
Sep 2023 0 0 350K

Accustem Sciences alternative data

Accustem Sciences Inc. (OTC:ACUT): Employee count
Oct 2023 4
Nov 2023 4
Dec 2023 4
Jan 2024 4
Feb 2024 4
Mar 2024 3
Apr 2024 3
May 2024 3
Jun 2024 3
Jul 2024 3

Accustem Sciences other data

Accustem Sciences Inc. (OTC:ACUT): Insider trades (number of shares)
Period Buy Sel
Apr 2022 9447 0
Jun 2022 20000 0
Aug 2022 10000 0
Nov 2022 24500 0
Dec 2022 8729 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 5,000 $1.4 $7,000
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 3,729 $1.42 $5,295
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 24,500 $1.05 $25,725
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 10,000 $0.79 $7,900
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 20,000 $0.5 $10,000
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 5,266 $1.49 $7,846
Purchase
CERRONE GABRIELE M director, 10 percent owner
Common Stock 4,181 $1.35 $5,644
  • What's the price of Accustem Sciences stock today?

    One share of Accustem Sciences stock can currently be purchased for approximately $1.78.

  • When is Accustem Sciences's next earnings date?

    Unfortunately, Accustem Sciences's (ACUT) next earnings date is currently unknown.

  • Does Accustem Sciences pay dividends?

    No, Accustem Sciences does not pay dividends.

  • What is Accustem Sciences's stock symbol?

    Accustem Sciences Inc. is traded on the OTC under the ticker symbol "ACUT".

  • What is Accustem Sciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Accustem Sciences?

    Shares of Accustem Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When Accustem Sciences went public?

    Accustem Sciences Inc. is publicly traded company for more then 5 years since IPO on 6 Aug 2020.

  • What is Accustem Sciences's official website?

    The official website for Accustem Sciences is accustem.com.

  • Where are Accustem Sciences's headquarters?

    Accustem Sciences is headquartered at 5 Penn Plaza, New York, NY.

  • How can i contact Accustem Sciences?

    Accustem Sciences's mailing address is 5 Penn Plaza, New York, NY.

Accustem Sciences company profile:

Accustem Sciences Inc.

accustem.com
Exchange:

OTC

Full time employees:

0

Industry:

Biotechnology

Sector:

Healthcare

Accustem Sciences Inc., a clinical stage diagnostics company, develops and commercializes products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was incorporated in 2021 and is headquartered in New York, New York.

5 Penn Plaza
New York, NY 10001

CIK: 0001850767
ISIN: US00444A1016
CUSIP: 00444A101